Stimulation of Beta-3 Adrenergic Receptors Modulated Sperm Motility and Morphology in Rat
Keywords:
Mirabegron, Beta3-receptor, Sperm, SQA vision, Sperm motilityAbstract
Mirabegron has different mechanism of actions by which it overcomes the adverse effects such as dry mouth and constipation associated with anti-muscarinic in current use for overactive urinary balder (OAB). The aim of this study was to determine the effect of Mirabegron on sperm activity and morphology. The study evaluated the activity of sperm cells after the use of mirabegron for three months by automated semen analysis by SQA Vision. Results show that mirabegron (6 mg/kg/day, orally) slightly increased the count and density of the sperms, increases the rate of deformity, and decreases the motility of the sperm cells. In conclusion, high dose and prolonged use of Mirabegron can potentially cause damage to sperm cells and result in reproductive toxicity although, it is safe at therapeutic dosage.
References
O’Mara AE, Johnson JW, Linderman JD, Brychta RJ, McGehee S, Fletcher LA, Fink YA, Kapuria D, Cassimatis TM, Kelsey N, Cero C. Chronic mirabegron treatment increases human brown fat, HDL cholesterol, and insulin sensitivity. J Clin Invest. 2020; 130(5):2209-2219.
Gerig N, Cameron T, Arora S, Spear J, Lescozec L, Zhang M. Do we need more patient‐friendly treatment options for overactive bladder (OAB)?. Neurourol Urodyn. 2021; 40(6):1433-1440.
Dehvari N, da Silva Junior ED, Bengtsson T, Hutchinson DS. Mirabegron: potential off-target effects and uses beyond the bladder. Br J Pharmacol. 2018; 175(21):4072-4082.
Kelleher C, Hakimi Z, Zur R, Siddiqui E, Maman K, Aballéa S, Nazir J, Chapple C. Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis. Eur Urol. 2018;
(3):324-333.
Finlin BS, Memetimin H, Zhu B, Confides AL, Vekaria HJ, El Khouli RH, Johnson ZR, Westgate PM, Chen J, Morris AJ, Sullivan PG. The β3-adrenergic receptor agonist mirabegron improves glucose homeostasis in obese humans. J Clin Invest. 2020; 130(5):2319-2331.
Griebling TL, Campbell NL, Mangel J, Staskin D, Herschorn S, Elsouda D, Schermer CR. Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR). BMC Geriatr. 2020; 20(1):1-0.
Wu TH, Shen YC, Lee WC, Wang HJ, Chuang YC. Effect of mirabegron on erectile function in sexually active men with bothersome overactive bladder symptoms. Intell Med. 2020; 83(1):55-59.
Okada H, Tokumoto T, Osaka A, Tanaka T, Iwahata T, Kobori Y, Saito K, Sato Y, Ban S, Sugimoto K. Does mirabegron deteriorate spermatogenesis? A lesson from spinal cord injury cases. LUTS Journal. 2021; 13(4):435-439.
Ni FD, Hao SL, Yang WX. Multiple signaling pathways in Sertoli cells: recent findings in spermatogenesis. Cell Death Dis. 2019; 10(8):1-5.
Tanaka M, Chiba K, Okada K, Fujisawa M. Effect of mirabegron on tight junction molecules in primary cultured rat Sertoli cells. Androl. 2019; 51(5):e13241.
Engel KM, Grunewald S, Schiller J, Paasch U. Automated semen analysis by SQA Vision® versus the manual approach—A prospective double‐blind study. Androl. 2019; 51(1):e13149.
Singh S, Sharma S, Jain M, Chauhan R. Importance of Papanicolaou staining for sperm morphologic analysis: comparison with an automated sperm quality analyzer. Am J Clin Pathol. 2011; 136(2):247-251.
Dostal LA, Faber CK, Zandee J. Sperm motion parameters in vas deferens and cauda epididymal rat sperm. Reprod Toxicol. 1996; 10(3):231-235.
Slott VL, Suarez JD, Poss PM, Linder RE, Strader LF, Perreault SD. Optimization of the Hamilton-Thorn computerized sperm motility analysis system for use with rat spermatozoa in toxicological studies. Fund Appl Toxicol. 1993; 21(3):298-307.
Chiba K, Kondo Y, Yamaguchi K, Miyake H, Fujisawa M. Inhibition of claudin‐11 and occludin expression in rat Sertoli cells by mono‐(2‐Ethylhexyl) phthalate through p44/42 mitogen‐activated protein kinase pathway. J Androl. 2012; 33(3):368-374.
Sacco E and Bientinesi R. Mirabegron: a review of recent data and its prospects in the management of overactive bladder. Ther Adv Urol. 2012; 4(6):315-324.
Yuno K, Onishi Y, Arima A, Zaizen K, Aoki Y, Nakagawa S, Schneidkraut MJ, Miyamae Y. Effect of mirabegron on plasma gonadotropic and steroidal hormone levels in rats after two weeks of oral administration. The J Toxicol Sci. 2014; 39(3):507-514.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
